Addex Therapeutics (ADXN) EBITDA (2022 - 2025)
Historic EBITDA for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to -$870270.5.
- Addex Therapeutics' EBITDA fell 2118.28% to -$870270.5 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year increase of 1747.23%. This contributed to the annual value of -$2.9 million for FY2024, which is 1724.84% down from last year.
- Per Addex Therapeutics' latest filing, its EBITDA stood at -$870270.5 for Q3 2025, which was down 2118.28% from -$885260.4 recorded in Q2 2025.
- In the past 5 years, Addex Therapeutics' EBITDA registered a high of -$718146.7 during Q3 2024, and its lowest value of -$21.3 million during Q4 2022.
- Its 4-year average for EBITDA is -$4.1 million, with a median of -$3.0 million in 2023.
- As far as peak fluctuations go, Addex Therapeutics' EBITDA skyrocketed by 8812.85% in 2023, and later crashed by 3631.51% in 2024.
- Quarter analysis of 4 years shows Addex Therapeutics' EBITDA stood at -$21.3 million in 2022, then surged by 88.13% to -$2.5 million in 2023, then dropped by 24.37% to -$3.1 million in 2024, then soared by 72.33% to -$870270.5 in 2025.
- Its EBITDA stands at -$870270.5 for Q3 2025, versus -$885260.4 for Q2 2025 and -$1.6 million for Q1 2025.